Vascular mineralocorticoid receptor activation and disease.
Aldosterone
Angiogenesis
Vascular injury
Journal
Experimental eye research
ISSN: 1096-0007
Titre abrégé: Exp Eye Res
Pays: England
ID NLM: 0370707
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
09
05
2019
revised:
09
09
2019
accepted:
10
09
2019
pubmed:
16
9
2019
medline:
29
2
2020
entrez:
16
9
2019
Statut:
ppublish
Résumé
Mineralocorticoid receptor activation in endothelial and smooth muscle cells can promote vascular disease by increasing oxidative stress, promoting inflammation, accelerating vascular stiffness, remodeling, and calcification, altering vessel responsiveness to various vasoactive factors, thus altering vascular tone and blood pressure, and by altering angiogenesis. Here, we review the recent evidence highlighting the impact of vascular mineralocorticoid receptor activation in pathological situations, including kidney injury, vascular injury associated with metabolic diseases, atherosclerosis, cerebral vascular injury during hypertension, vascular stiffening and aging, pulmonary hypertension, vascular calcification, cardiac remodeling, wound healing, inflammation, thrombosis, and disorders related to angiogenic defects in the eye. The possible mechanisms implicating mineralocorticoid receptor activation in various vascular disorders are discussed. Altogether, recent evidence points towards pharmacological mineralocorticoid receptor inhibition as a strategy to treat diseases in which overactivation of the mineralocorticoid receptor in endothelial and/or smooth muscle cells may play a pivotal role.
Identifiants
pubmed: 31521629
pii: S0014-4835(19)30329-X
doi: 10.1016/j.exer.2019.107796
pii:
doi:
Substances chimiques
Receptors, Mineralocorticoid
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
107796Informations de copyright
Copyright © 2019. Published by Elsevier Ltd.